Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)
239.00
+17.20 (7.75%)
At close: Apr 29, 2026
HKG:2637 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Cash & Equivalents | 645.05 | 38.28 | 254.32 | 171.48 |
| Short-Term Investments | 151.86 | - | 20.27 | 120.35 |
| Trading Asset Securities | 533.55 | 234.96 | - | 20.34 |
| Cash & Short-Term Investments | 1,330 | 273.24 | 274.6 | 312.17 |
| Cash Growth | 386.93% | -0.50% | -12.04% | - |
| Accounts Receivable | 29.63 | 22.45 | 22.2 | 6.09 |
| Other Receivables | 24.3 | 15.24 | 12.24 | 3.54 |
| Receivables | 53.92 | 37.69 | 34.43 | 9.63 |
| Inventory | 56.1 | 35.33 | 24.8 | 28.37 |
| Total Current Assets | 1,440 | 346.26 | 333.83 | 350.17 |
| Property, Plant & Equipment | 328.42 | 309.55 | 129.53 | 16.63 |
| Long-Term Investments | 43.67 | 50.89 | 20 | - |
| Other Intangible Assets | 0.13 | - | - | - |
| Long-Term Deferred Tax Assets | 4.42 | 5.87 | 9.42 | 24.78 |
| Other Long-Term Assets | 29.58 | 43.26 | 68.76 | 29.38 |
| Total Assets | 1,847 | 755.82 | 561.54 | 420.96 |
| Accounts Payable | 15.86 | 15.78 | 2.8 | 3.11 |
| Accrued Expenses | 77.48 | 52.52 | 37.12 | 15.83 |
| Current Portion of Long-Term Debt | 83.98 | 23.12 | 9.6 | 48.45 |
| Current Portion of Leases | 1.62 | 1.51 | 1.44 | 0.87 |
| Current Income Taxes Payable | 8.85 | 5.08 | - | 0.01 |
| Current Unearned Revenue | 1.91 | 8.05 | 0.26 | 1.98 |
| Other Current Liabilities | 38.58 | 76.02 | 65.82 | 19.84 |
| Total Current Liabilities | 228.28 | 182.07 | 117.04 | 90.09 |
| Long-Term Debt | 19.77 | 26.62 | 31.92 | 35.95 |
| Long-Term Leases | 4.78 | 5.62 | 7.14 | 6.91 |
| Long-Term Unearned Revenue | 0.14 | 0.17 | 0.2 | 0.23 |
| Total Liabilities | 252.97 | 214.49 | 156.3 | 133.18 |
| Common Stock | 78.71 | 67.21 | 67.21 | 67.21 |
| Retained Earnings | - | 254.59 | 118.51 | 1.06 |
| Comprehensive Income & Other | 1,515 | 219.53 | 219.53 | 219.51 |
| Shareholders' Equity | 1,594 | 541.33 | 405.25 | 287.78 |
| Total Liabilities & Equity | 1,847 | 755.82 | 561.54 | 420.96 |
| Total Debt | 110.15 | 56.88 | 50.09 | 92.18 |
| Net Cash (Debt) | 1,220 | 216.36 | 224.51 | 219.99 |
| Net Cash Growth | 464.03% | -3.63% | 2.05% | - |
| Net Cash Per Share | 17.56 | 3.22 | 3.34 | 3.42 |
| Filing Date Shares Outstanding | 78.71 | 67.21 | 67.21 | 64.27 |
| Total Common Shares Outstanding | 78.71 | 67.21 | 67.21 | 64.27 |
| Working Capital | 1,212 | 164.19 | 216.79 | 260.09 |
| Book Value Per Share | 20.25 | 8.05 | 6.03 | 4.48 |
| Tangible Book Value | 1,594 | 541.33 | 405.25 | 287.78 |
| Tangible Book Value Per Share | 20.25 | 8.05 | 6.03 | 4.48 |
| Machinery | - | 25.87 | 24.51 | 19.76 |
| Construction In Progress | - | 263.2 | 80.08 | - |
| Leasehold Improvements | - | 3.09 | 2.72 | 2.72 |
Source: S&P Capital IQ. Standard template. Financial Sources.